Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News LianBio (PK) LIANY

Healthcare Biotechnology
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex... see more

Current News (PINL:LIANY)

LianBio Announces Voluntarily Delisting from Nasdaq

GlobeNewswire February 28, 2024

LianBio Announces Completion of Strategic Review

GlobeNewswire February 13, 2024

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

GlobeNewswire December 26, 2023

LianBio Announces Departure of Chief Financial Officer

GlobeNewswire December 20, 2023

LianBio Announces Departure of Chief Executive Officer

GlobeNewswire December 19, 2023

LianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

GlobeNewswire December 6, 2023

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

GlobeNewswire December 1, 2023

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

GlobeNewswire October 30, 2023
View More News ››

Opinion & Analysis (PINL:LIANY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:LIANY)

Be the first to post on this bullboard.

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts